EKF Diagnostics - Interim results

Tuesday, Oct 04 2011 by

EKF Diagnostics, the point of care diagnostics company, announced that Interim results to June 2011 (with pro-forma comparative results) showed sales of £7.4 million (2010: £6.0 million) and adjusted EBITDA of £210,000 (2010: £(51,000)). The pre-tax loss was £1.55 million (2010: £(302,000)), actual not pro-forma.

The company reported that the period was impacted by the costs involved in moving from an essentially owner-managed structure and culture to one that is more reflective of the demands of a higher-growth/higher governance led environment. Gross margin was 64% (2010: 58%). Period end net cash was £2.8 million.

The EKF share price has increased by 3% over the past year.

EKF Diagnostic Holdings Plc is currently graded C by LCF Research. To learn more, follow the link.


This note was prepared by LCF Research Limited using information provided by the subject company’s management or publically available news sources. No representations are made nor warranties given (express or implied) in relation to accuracy and completeness. This document is not an invitation to invest in the subject company and does not purport to contain all the necessary information that a prospective investor might require. LCF Research Limited recommends prospective investors to conduct their own thorough independent analysis of the subject company and the information contained in this note or referred to above.

Do you like this Post?
0 thumbs up
0 thumbs down
Share this post with friends

EKF Diagnostics Holdings Plc designs, develops, manufactures and sells diagnostic instruments, reagents and certain ancillary products. The Company is focused within the In-Vitro Diagnostic devices (IVD) market place. Other services include the servicing and distribution of other company products under separate distribution agreements. The Company operates in the United States, Germany, Poland, Russia, United Kingdom and Ireland. The Company is also a manufacture and distribution of organ injury biomarkers specializing in acute injury to kidneys (AKI), liver and pancreas. In March 2014, EKF Diagnostics Holdings PLC acquired Separation Technology Inc. more »

Share Price (AIM)
0.9  4.2%
P/E (fwd)
Yield (fwd)
Mkt Cap (£m)

  Is EKF Diagnostics Holdings fundamentally strong or weak? Find out More »

What's your view on this thread? to Comment Now

You are feeling neutral

Use the £ sign in front of a ticker to turn £VOD into Vodafone PLC

You can track all @StockoChat comments via Twitter

Stock Picking Tutorial Centre

Stock Picking Simplified

Stockopedia takes your stock picking to the next level with cutting edge Stock Reports & Screening tools.

Get started
or Take a Tour to find out more.